



Drug Price Transparency Rule Advisory Committee Meeting

Aug. 22, 2024



Division of
Financial
Regulation

Department of Consumer
and Business Services

Welcome!

Agenda:

- Introductions
- Process overview & background
- Review draft rules
 - Questions
 - Discussion
- Public comment
- Next steps

Introductions

Committee roster:

- BethAnn Darby – Oregon Coalition for Affordable Prescriptions
- Brett Michelin – Association for Accessible Medicines
- Charlie Fisher – OSPIRG
- Dharia McGrew – PhRMA
- Eric Chung – Pyros Pharmaceuticals
- Gregory Halen – Par Pharmaceuticals
- Lynetta Moore – Integrichain
- Melody Calkins – BIO and BIO Oregon
- Robert Judge - Moda Health

Housekeeping

- Video off, line muted if not speaking
- Raise hands to speak
- Chat is open
- Time reserved for public comment
- Request for written comment

Rulemaking overview

- Rule: Any agency directive, standard, regulation or statement of general applicability that implements, interprets or prescribes law or policy...
 - See ORS 183.310(9)
 - Has weight of law
 - Must be consistent with statute

Rulemaking overview

- Role of Advisory Committee
 - Represent interests of those likely to be affected by rules
 - Provide advice and recommendations
- Adoption process
 - Notice
 - Public comment
 - Public hearing

Background for revisions

- 5-year review
- General updates
 - Citations
 - Outdated timing requirements
- Easing administrative burdens (for DFR and manufacturers)
 - Definition clarifications
 - Details added for regularly misunderstood requirements
- Increasing clarity
 - Streamlining reporting requirements

836-200-0505

Definitions

- Questions for RAC
 - Does added specificity to “new prescription drug” and “reporting manufacturer” provide needed clarification?
- Are there other terms that would benefit from adding a definition?
 - Will revisit at the end of the process

836-200-0510

Account Generation Requirement

- Questions for RAC
 - Any additional clarity needed for the new contact requirements?

836-200-0520

Threshold for Reporting New Prescription Drugs

- Questions for RAC
 - Are additional details about the “date of introduction” needed?

836-200-0530

Form and Manner Requirements for Drug Pricing Reporting

- Questions for RAC
 - Additional clarity needed regarding the changes to make the annual drug price increase reporting voluntary?

Public comment

Next steps

- Written comments due – Close of business on Sept. 9
- Next meeting – Sept. 19, 12:30 – 2 p.m. (tentative)
- Division contacts:

Lily Sobolik

Sr. Policy Advisor

DCBS | Division of Financial Regulation

Lily.Sobolik@dcbs.oregon.gov

971-446-8813

Pronouns: she/her/hers

Karen Winkel

Rules Coordinator

DCBS | Division of Financial Regulation

Karen.J.Winkel@dcbs.oregon.gov

503-947-7694

Pronouns: she/her/hers